PD34-11 PROSTATE-SPECIFIC ANTIGEN KINETICS IN PATIENTS WITH ADVANCED PROSTATE CANCER TREATED WITH APALUTAMIDE: RESULTS FROM THE TITAN AND SPARTAN STUDIES

You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) III (PD34)1 Sep 2021PD34-11 PROSTATE-SPECIFIC ANTIGEN KINETICS IN PATIENTS WITH ADVANCED PROSTATE CANCER TREATED APALUTAMIDE: RESULTS FROM THE TITAN AND SPARTAN STUDIES Kim N. Chi, Fred Saad, Simon Chowdhury, Julie Graff, Neeraj Agarwal, Stéphane Oudard, Gang Li, Angela Lopez-Gitlitz, S. Larsen, Sharon A. McCarthy, Suneel D. Mundle, Matthew R. Smith, and Eric J. Small ChiKim Chi More articles by this author , SaadFred Saad ChowdhurySimon Chowdhury GraffJulie Graff AgarwalNeeraj Agarwal OudardStéphane Oudard LiGang Li Lopez-GitlitzAngela Lopez-Gitlitz LarsenJulie Larsen McCarthySharon McCarthy MundleSuneel Mundle SmithMatthew Smith SmallEric View All Author Informationhttps://doi.org/10.1097/JU.0000000000002038.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION OBJECTIVE: The phase 3 studies demonstrated improved outcomes with the addition apalutamide (APA) androgen deprivation therapy (ADT); included prolonging overall survival radiographic progression-free (rPFS) in metastatic castration-sensitive prostate cancer (mCSPC) TITAN, metastasis-free (MFS) nonmetastatic castration-resistant PC (nmCRPC) SPARTAN. A post hoc analysis prostate-specific antigen kinetics (PSA) patients (pts) from both is reported. METHODS: Baseline PSA at randomization, time nadir, proportion pts achieving a decline ≥90% (PSA90) PSA≤0.2 ng/mL 12 months any after treatment APA arms were evaluated. Within each study, rPFS/MFS compared between PSA90 or response vs not. RESULTS: 525 806 treated analysis. Median baseline PSA, median maximum percentage changes are shown table. confirmed evident as early SPARTAN, continued increase months. Pts who achieved lower risk rPFS events MFS hazard ratio (95% confidence interval) 0.46 (0.321-0.653) 0.36 (0.271-0.489) respective study (both p<0.0001), did not achieve PSA90. had similar benefits. CONCLUSIONS: advanced PC, whether mCSPC nmCRPC, APA+ADT rapid declines that over time. There was high rate responses, majority reaching and/or nadir ≤0.2 prolonged respectively. Source Funding: Janssen Research & Development © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e587-e587 Advertisement Copyright Permissions© Inc.MetricsAuthor Information Expand Loading ...